U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07004647) titled 'MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors' on April 14.
Brief Summary: This study is a single-arm, dose-escalation, investigator-initiated exploratory clinical trial designed to evaluate the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of MT027 Cell Injection in patients with advanced primary or secondary peritoneal tumors.
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Peritoneal Tumor
Intervention:
DRUG: Fludarabine
D-10 to D-2: Fludarabine (25 mg/m2/day) will be administered intravenously for 3 days;D-10 to D-2: Cyclophosphamide (250 mg...